Probenecid to reduce alcohol craving and consumption
Official title: Probenecid, Pannexin 1 Channels for Alcohol Use Disorder
Run by Brown University · NCT07118618 · Data updated 2026-11-12
This trial will test whether taking daily probenecid (2 g/day) reduces craving and drinking in adults with moderate-to-severe alcohol use disorder.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | Brown University Academic / other |
| Drugs / interventions | methotrexate |
| Locations | 1 site (Providence, Rhode Island) |
| Status | Recruiting |
| Started | March 14, 2026 |
| Main results expected | December 31, 2030 |
| Study ends | December 31, 2030 |
| Registry record updated | March 17, 2026 |
| Trial ID | NCT07118618 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with moderate-to-severe AUD who drink more than 7 drinks/week for women or 14 drinks/week for men, have BrAC=0.00 at visits, and meet safety lab and clinic visit requirements are ideal candidates.
✕Probably not a fit
People who are pregnant or breastfeeding, have significant liver or kidney dysfunction, active psychotic or bipolar disorders, or who take contraindicated medications (for example naltrexone, methotrexate, penicillin, or regular aspirin) are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Over 16 weeks, adults with moderate-to-severe AUD will be randomized in a double-blind, placebo-controlled Phase 2 trial to receive probenecid 2 g/day or matching placebo. The study includes a laboratory phase measuring acute alcohol craving and naturalistic phases tracking craving and real-world alcohol consumption. Participants will have regular clinical visits with safety labs and symptom questionnaires, and outcomes will compare changes in craving and drinking between the probenecid and placebo groups. Screening excludes people with significant liver, kidney, or certain psychiatric conditions and those taking contraindicated medications.
Why it matters
Potential benefit: If successful, probenecid could offer a repurposed medication to help reduce craving and lower alcohol use in people with AUD.
How similar studies have gone: This is a novel repurposing approach with limited prior clinical data for probenecid in AUD, so evidence to date is preliminary rather than established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * • Male or female, ≥18 years. * women \>7 drinks/week; men \>14 drinks/week. * meet moderate to severe AUD score for DSM-5 criteria. * Breath Alcohol Content (BrAC)=0.00 at each visit. * in good health as confirmed by medical history, physical examination and lab tests. * willing to adhere to the study procedures. * understand informed consent and questionnaires in English at an 8th grade level. Exclusion Criteria: * • Women who are breastfeeding or positive urine test for pregnancy. * clinically significant medical abnormalities: unstable hypertension, clinically significant abnormal EKG, bilirubin \>150% of the upper normal limit, ALT/AST \>300% the UNL, creatinine clearance ≤60 dl/min * meet DSM-5 criteria for a diagnosis of schizophrenia, bipolar disorder, or other psychoses * medications that reduce alcohol consumption (naltrexone, disulfiram). * use aspirin (salicylates may reduce effect of probenecid), penicillin, methotrexate (may increase concentration). * history of suicide attempts in the last three years. * current diagnosis of a moderate or severe cannabis use disorder as assessed by self-report, SCID-E for SUD, and urine toxicology screen at baseline. * current diagnosis of another substance disorder at any severity, other than nicotine, as assessed by self-report, SCID-E for SUD, and urine toxicology screen at baseline. * current use of medications that may interact with probenecid. * history of hypersensitivity to sulfa drugs.
Where it's running
-
Brown University
Providence, Rhode Island, United States Recruiting
Study contacts
- Principal investigator: Carolina Haass-Koffler, PharmD, PhD — Brown Univiversity
- Study coordinator: Brian Gully, MA
- Email: brian_gully@brown.edu
- Phone: 401-863-6646
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Can CBD help with alcohol withdrawal and craving
This study tests whether cannabidiol (CBD) given with standard care can reduce withdrawal symptoms and craving in adults with moderate-to-severe alcohol use disorder during a short inpatient withdrawal period.
-
Effects of Mavoglurant on Alcohol Craving and Drinking in Heavy Drinkers
This study is testing if a new drug called mavoglurant can help heavy drinkers with Alcohol Use Disorder reduce their cravings and drinking.
-
Chromium Picolinate for Appetite and Cravings in Overweight Adults
A remote 8-week program tests whether daily chromium picolinate helps reduce hunger and cravings in adults with BMI 25–31 who are overweight.
-
Imaging Mitochondrial Complex-I and Brain Metabolism in Alcohol Use Disorder
This study tests whether PET imaging with [18F]BCPP-EF and [18F]FDG can reveal differences in brain energy use between adults with alcohol use disorder and healthy controls, and whether these measures relate to relapse risk.
-
Endurance exercise to see if it lowers alcohol use in adults with AUD and ALD
A 12-week home-based cycling program added to standard care is tested to see if it reduces alcohol use and cravings in adults with alcohol use disorder and alcohol-related liver disease.
-
Do beverage cues drive craving in adults with AUD
In adults with alcohol use disorder, this study tests whether different non-alcoholic beverage cues can trigger cravings differently when people see and smell them without drinking.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.